-
Indicted Raul Castro reappears after months out of public view
-
Israel reopens once-closed West Bank settlement
-
Italian teen Curtis breaks women's 50m backstroke world record for second time
-
Taylor to captain New Zealand for first time against Bulls
-
Taulagi steps out of 'comfort zone' with code switch to French Top 14 new boys
-
Carrick urges Man Utd to push for more signings to boost title bid
-
Leicester's Thai owners put troubled club up for sale: reports
-
'This was my World Cup' says Somali ref after UEFA Super Cup
-
Stocks steady as US inflation worries ease, oil slips
-
Survivors tell of horror of Zimbabwe ferry sinking as death toll hits 46
-
Porsche to end production of flagship electric car: report
-
Juventus forward Vlahovic signs three-year Besiktas deal
-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
-
Blaze forces families to abandon Turkish tour boat
-
Stocks gain as US inflation worries ease, oil slips
-
'If you can, move!' say Rome's viral dancing seniors
-
Heavy rain soaks eastern Japan, prompting highest-level warning
-
Zambia voters weigh Hichilema's economic record
-
Celtic boss O'Neill 'much better' after hospital procedure
-
SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026
-
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
-
Hodgkinson sets up Werro showdown after Euro 800m drama
-
Maghreb sees demographic shift with fertility at historic low
-
'How many will die?': the mysterious ailment killing Kenyan elephants
-
European stocks gain as oil prices ease
-
Arteta coy over Lewis-Skelly's Arsenal future after 'emotional' celebration
-
Infantino future should be decided by election says African football chief
-
Romania shuts down nuclear plant as Danube drops
-
Man City star Doku signs five-year contract extension
-
German steel giant Thyssenkrupp weighs options as Rhine drops
-
Fabien Barthez joins Zidane's new France coaching setup
-
US ambassador denounces settler siege as Israel dispatches troops
-
Taiwan chokes mobile internet speeds in drill for Chinese attack
-
Hasan takes 6-55 as Bangladesh claim opening day of Australia Test
-
From Chinese AI to Global ETFs: STARTRADER Launches 45 New 24/7 Stock and ETF CFDs
-
Taiwan says AI agents used in cyberattacks targeting island
-
Tech stocks enjoy rebound after US inflation on mixed day for markets
-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
Cannabis extract relieves chronic back pain: high-quality trial
A specially developed cannabis extract relieves chronic lower back pain, according to a clinical trial published Wednesday that experts are calling the first high-quality evidence that something in the cannabis plant can treat pain.
Lower back pain is the leading cause of disability worldwide, affecting more than half a billion people, according to the World Health Organization.
But drugs for chronic back pain are limited to common painkillers such as ibuprofen, which can have serious side effects when used long-term, or highly addictive and potentially dangerous opioids.
In recent years, an expanding cannabis industry has claimed that a range of marijuana or cannabidiol (CBD) products can help with pain, but researchers have warned that the quality of evidence actually showing this has been low.
On Wednesday, a large placebo-controlled, phase 3 clinical trial -- which is considered the gold standard for researching medical drugs -- testing a cannabis extract was published in the journal Nature Medicine.
The trial involved more than 800 people with chronic lower back pain who did not get relief from non-opioid drugs.
After 12 weeks of taking either the cannabis extract called VER-01 or a placebo, participants were asked to report their pain level on a 10-point scale.
Those taking the extract reported a 1.9-point reduction in pain, compared to 0.6 for those on the placebo.
After six months, participants taking the extract said their pain had decreased by a higher 2.9 points.
They also reported better sleep, physical function and quality of life, according to the study.
Each dose of VER-01 contains 2.5 milligrammes of THC, the main active ingredient in marijuana.
Nothing suggested that the extract was addictive or caused serious side effects, the study said. The most common side effects were short-term dizziness, sleepiness, dry mouth and some nausea -- though they decreased over time.
The study's lead author Matthias Karst, a professor of pain medicine at Hannover Medical School in Germany, told AFP that "no feelings of (being) high" were observed during the trial.
- 'As good as it gets' -
Andrew Moore, a former pain researcher at Oxford University not involved in the study, said the "terrific" trial was "about as good as it gets".
"The trial is the first that shows good quality evidence that something in the cannabis plant can be helpful for pain," he told AFP.
But Moore also urged caution about claims that the extract was not addictive, warning that in the past, such statements have later turned out to be incorrect.
Most cannabis products vary widely in potency, purity and other factors which make them difficult for doctors to safely prescribe, Karst said.
The VER-01 strain has been specifically developed to obtain approval by medical authorities and then be prescribed for chronic pain, he added.
This means the study is not "proof that all cannabis/CBD products would be helpful in the same way," Karst emphasised.
Jan Vollert, a pain researcher at Exeter University not involved in the study, also stressed the difference between this "very specific substance" and regular marijuana.
"Smoking cannabis and taking VER-01 are probably as similar as eating hazelnuts and eating Nutella: they might share a similar basis, but they just are not comparable," he said.
L.AbuTayeh--SF-PST